CareDx reports strong third quarter and raises 2026 outlook
CareDx reported $139 million in revenue for the quarter ended September 30, 2026, up 39% year over year. Testing Services revenue increased 65% to $119 million, while adjusted EBITDA doubled to $30 million. The company raised its 2026 revenue guidance to $520 million-$530 million and adjusted EBITDA guidance to $90 million-$100 million, and said AlloHeme is targeted for commercial launch in the first quarter of 2027.
Why it matters
The higher outlook gives investors updated 2026 sales and profitability ranges. CareDx's planned 2027 product launches add future commercialization milestones, while the guidance figures raise the financial expectations attached to the business.
Key facts
- 1Revenue for the quarter ended September 30, 2026, was $139 million, compared with $100 million a year earlier. rttnews.com
- 2Testing Services revenue rose 65% to $119 million, and testing volume increased 51% to approximately 75,900. rttnews.com
- 3CareDx increased its full-year 2026 revenue guidance to $520 million-$530 million from $490 million-$500 million. rttnews.com
- 4The company raised its 2026 adjusted EBITDA guidance to $90 million-$100 million from $66 million-$78 million. rttnews.com
- 5CareDx is targeting a first-quarter 2027 commercial launch for AlloHeme and broader commercial availability of HistoMap Kidney in 2027. rttnews.com
Open questions
- Material 5 describes the raised full-year revenue guidance as $525M, while materials 2, 3 and 4 report a $520 million-$530 million range; the company's precise guidance figure is therefore inconsistent across the materials.
- Reported share-price gains vary across the materials, ranging from 14% to 24%, reflecting different trading points or reporting times.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.